[Clinical evaluation of flomoxef in pediatrics and a study on the penetration into cerebrospinal fluid].

Abstract

The transfer to cerebrospinal fluid of a new oxacephem antibiotic flomoxef (FMOX, 6315-S) and its clinical efficacy against bacterial infections were investigated. 1. In 3 cases of purulent meningitis, cerebrospinal fluid concentrations of FMOX after one shot intravenous injection of 100 mg/kg during the acute stage of infections were 5.12-6.32 micrograms/ml and ratios of FMOX in cerebrospinal fluid in serum were about 5%. During the recovery stage, cerebrospinal fluid concentrations were about 3.8 micrograms/ml and cerebrospinal fluid/serum ratios were about 3.5%. 2. In 1 case of purulent meningitis, the treatment with FMOX was clinically effective but this case was classified as "unevaluable" because other drug was used concomitantly. FMOX was rated effective in other 2 cases of purulent meningitis. Of 9 cases of pneumonia, FMOX was rated very effective in 8 cases and it was rated only effective in the other. Of 4 cases of bronchitis, the drug was rated very effective in 3 cases and only effective in the other. FMOX was rated very effective against 2 cases of tonsillitis, also. 3. As side effects, thrombocytosis was observed in 3 of 20 cases examined. All cases, however, were deemed unrelated to the FMOX treatment and the side effect was only transient as are often found in courses of recovery from infections.

• Authors: T Okada, S Furukawa
• Journal: The Japanese journal of antibiotics (Jpn J Antibiot) Vol. 40 Issue 8 Pg. 1477-85 (Aug 1987) ISSN: 0368-2781 [Print] Japan
• PMID: 3430723 (Publication Type: Case Reports, English Abstract, Journal Article)

Chemical References

• Cephalosporins
• flomoxef

Topics

• Age Factors
• Bacteria (isolation & purification)
• Bacterial Infections (cerebrospinal fluid, drug therapy, microbiology)
• Cephalosporins (adverse effects, cerebrospinal fluid, therapeutic use)
• Child
• Child, Preschool
• Drug Evaluation
• Female
• Humans
• Infant
• Male